CNS Pharmaceuticals (CNSP) Competitors $0.89 -0.04 (-4.30%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNSP vs. ENLV, QTTB, MIRA, FNCH, JATT, NAII, BIVI, SNYR, MTEX, and BLRXShould you be buying CNS Pharmaceuticals stock or one of its competitors? The main competitors of CNS Pharmaceuticals include Enlivex Therapeutics (ENLV), Q32 Bio (QTTB), MIRA Pharmaceuticals (MIRA), Finch Therapeutics Group (FNCH), JATT Acquisition (JATT), Natural Alternatives International (NAII), BioVie (BIVI), Synergy CHC Corp. (Uplisting) (SNYR), Mannatech (MTEX), and BioLineRx (BLRX). These companies are all part of the "pharmaceutical products" industry. CNS Pharmaceuticals vs. Its Competitors Enlivex Therapeutics Q32 Bio MIRA Pharmaceuticals Finch Therapeutics Group JATT Acquisition Natural Alternatives International BioVie Synergy CHC Corp. (Uplisting) Mannatech BioLineRx Enlivex Therapeutics (NASDAQ:ENLV) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership. Which has preferable valuation and earnings, ENLV or CNSP? Enlivex Therapeutics is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnlivex TherapeuticsN/AN/A-$29.07M-$0.66-1.42CNS PharmaceuticalsN/AN/A-$18.85M-$3.75 thousand0.00 Which has more risk & volatility, ENLV or CNSP? Enlivex Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, CNS Pharmaceuticals has a beta of 2.65, meaning that its share price is 165% more volatile than the S&P 500. Does the media refer more to ENLV or CNSP? In the previous week, Enlivex Therapeutics had 1 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 4 mentions for Enlivex Therapeutics and 3 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.96 beat Enlivex Therapeutics' score of 0.47 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CNS Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ENLV or CNSP? Enlivex Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 963.83%. CNS Pharmaceuticals has a consensus target price of $25.00, indicating a potential upside of 2,708.99%. Given CNS Pharmaceuticals' higher probable upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Enlivex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33CNS Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is ENLV or CNSP more profitable? CNS Pharmaceuticals' return on equity of 0.00% beat Enlivex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enlivex TherapeuticsN/A -67.57% -58.45% CNS Pharmaceuticals N/A N/A -515.32% Does the MarketBeat Community prefer ENLV or CNSP? Enlivex Therapeutics received 11 more outperform votes than CNS Pharmaceuticals when rated by MarketBeat users. Likewise, 81.08% of users gave Enlivex Therapeutics an outperform vote while only 70.00% of users gave CNS Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEnlivex TherapeuticsOutperform Votes6081.08% Underperform Votes1418.92%CNS PharmaceuticalsOutperform Votes4970.00% Underperform Votes2130.00% Do insiders and institutionals have more ownership in ENLV or CNSP? 1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by insiders. Comparatively, 0.1% of CNS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryEnlivex Therapeutics beats CNS Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get CNS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNSP vs. The Competition Export to ExcelMetricCNS PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.86M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.018.6727.1419.96Price / SalesN/A262.53411.83157.63Price / CashN/A65.8538.2534.64Price / Book-0.026.597.064.69Net Income-$18.85M$143.75M$3.23B$248.14M7 Day Performance-11.88%3.72%2.67%2.39%1 Month Performance-26.45%11.01%8.82%6.05%1 Year Performance-99.43%3.87%31.44%13.60% CNS Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNSPCNS Pharmaceuticals2.2637 of 5 stars$0.89-4.3%$25.00+2,709.0%-99.5%$4.86MN/A-0.015Short Interest ↓Gap DownENLVEnlivex Therapeutics3.4669 of 5 stars$0.94-2.8%$10.00+963.8%-33.7%$22.23MN/A-0.9670News CoverageUpcoming EarningsQTTBQ32 Bio3.4341 of 5 stars$1.82-4.2%$24.71+1,257.9%-91.5%$22.20M-$6.65M-0.1339Positive NewsShort Interest ↓MIRAMIRA Pharmaceuticals3.3749 of 5 stars$1.29-7.9%$14.00+985.3%+61.3%$21.83MN/A-2.302Short Interest ↓FNCHFinch Therapeutics Group0.3559 of 5 stars$13.39-1.3%N/A+885.6%$21.79M$110K-1.52190JATTJATT AcquisitionN/A$1.26+9.6%N/A-66.0%$21.74MN/A0.003High Trading VolumeNAIINatural Alternatives International0.7815 of 5 stars$3.44+0.6%N/A-48.0%$21.25M$125.48M-2.67290News CoveragePositive NewsShort Interest ↑BIVIBioVie2.4796 of 5 stars$1.12+3.7%$3.00+167.9%+124.3%$20.80MN/A-0.1110SNYRSynergy CHC Corp. (Uplisting)3.8181 of 5 stars$2.16+2.9%$10.00+363.0%N/A$19.86M$33.59M0.0040News CoverageMTEXMannatech1.2009 of 5 stars$10.39-2.6%N/A+30.8%$19.76M$115.04M-12.83250Short Interest ↓Gap DownBLRXBioLineRx3.485 of 5 stars$5.93+3.3%$26.00+338.4%-80.0%$19.74M$22.34M-0.6740Gap DownHigh Trading Volume Related Companies and Tools Related Companies ENLV Competitors QTTB Competitors MIRA Competitors FNCH Competitors JATT Competitors NAII Competitors BIVI Competitors SNYR Competitors MTEX Competitors BLRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNSP) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
